Key Takeaways
- • Buckley Capital delivered a 36.1% return in Q2 2026, continuing strong momentum from April gains of approximately 13% MTD and 8% YTD net through March 31, 2026.
- • The fund established a new long position in Molson Coors Beverage Company (NYSE: TAP) during Q2 2026, alongside new positions in The Clorox Company (CLX) and Vontier Corp, reflecting concentrated activity in the consumer and industrials sectors.
- • Buckley Capital's 13F portfolio stood at $139.15M as of March 31, 2026, down from $142.09M in the prior period, maintaining its value-oriented approach focused on 12–15 core positions in North American small and mid-cap equities.
- • The fund's investment thesis emphasizes asymmetric risk-reward opportunities with limited downside and meaningful upside potential, supported by differentiated research including alternative data and primary investigative work; since 2020, the fund has outperformed benchmarks by more than 10% annually.
- • Molson Coors shares gained 20.75% over the trailing 52-week period despite a one-month decline of 3.99%, suggesting volatility in the beverage sector that Buckley Capital may view as a valuation opportunity aligned with its core investment discipline.
Summary
Buckley Capital Advisors delivered strong second-quarter 2026 performance, capitalizing on momentum established in the first four months of the year. The fund's Q2 returns of 36.1% extended gains from an exceptionally robust April performance, when the fund had appreciated approximately 13% month-to-date net of fees. Through the first quarter ending March 31, 2026, the fund was up approximately 8% year-to-date net, reflecting consistent outperformance aligned with the manager's historical track record of exceeding benchmarks by more than 10% annually since 2020.
During Q2, Buckley Capital added three new positions to its concentrated portfolio, including Molson Coors Beverage Company (TAP), The Clorox Company (CLX), and Vontier Corp. The entry into Molson Coors reflects the fund's opportunistic positioning within the beverage sector, which has exhibited volatility despite longer-term strength—TAP shares declined 3.99% over the prior month but have appreciated 20.75% over the trailing 52-week period. This adds a beverage holding to Buckley Capital's North American consumer-focused strategy.
As of March 31, 2026, Buckley Capital's 13F portfolio was valued at $139.15M, down marginally from $142.09M in the preceding reporting period, reflecting the fund's concentrated, active management approach. The fund typically maintains 12–15 core positions across small and mid-cap equities, with particular emphasis on North American consumer stocks, financials, healthcare, and industrials. The portfolio construction reflects a private equity mindset applied to public markets, with each position supported by differentiated research developed through rigorous due diligence and alternative data sources.
The fund's investment discipline targets high-quality businesses trading at attractive valuations with asymmetric risk-reward profiles. Management emphasizes positions with limited downside and meaningful upside potential, evaluated through a long-term ownership lens rather than short-term trading dynamics. This approach, combined with the fund's demonstrated ability to identify mispriced opportunities across inefficiently priced market segments, has sustained consistent outperformance throughout the 2020–2026 period.
During Q2, Buckley Capital added three new positions to its concentrated portfolio, including Molson Coors Beverage Company (TAP), The Clorox Company (CLX), and Vontier Corp. The entry into Molson Coors reflects the fund's opportunistic positioning within the beverage sector, which has exhibited volatility despite longer-term strength—TAP shares declined 3.99% over the prior month but have appreciated 20.75% over the trailing 52-week period. This adds a beverage holding to Buckley Capital's North American consumer-focused strategy.
As of March 31, 2026, Buckley Capital's 13F portfolio was valued at $139.15M, down marginally from $142.09M in the preceding reporting period, reflecting the fund's concentrated, active management approach. The fund typically maintains 12–15 core positions across small and mid-cap equities, with particular emphasis on North American consumer stocks, financials, healthcare, and industrials. The portfolio construction reflects a private equity mindset applied to public markets, with each position supported by differentiated research developed through rigorous due diligence and alternative data sources.
The fund's investment discipline targets high-quality businesses trading at attractive valuations with asymmetric risk-reward profiles. Management emphasizes positions with limited downside and meaningful upside potential, evaluated through a long-term ownership lens rather than short-term trading dynamics. This approach, combined with the fund's demonstrated ability to identify mispriced opportunities across inefficiently priced market segments, has sustained consistent outperformance throughout the 2020–2026 period.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.